We told you about the dangerous parallels between GlaxoSmithKline's diabetes drug Avandia and Warner-Lambert's now-dead TZD Rezulin.
The New England Journal of Medicine has published a piece on making the same connection by Jerry Avorn, a Harvard Medical School professor. I think this quote from Avorn says it all on how he feels about FDA's advisory committee vote (almost unanimous) July 30 to keep Avandia on the market:
"The decision was more suggestive of Rezulin redux (and of Redux) than it was of resolve."You all remember Redux don't you? To read the whole Avorn piece, click here. As always, your comments are welcome.